The price of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares last traded on Wall Street rose 11.68% to $3.92.
Based on available information, 10 analysts follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $5.00, we find $8.00. Given the previous closing price of $3.51, this indicates a potential upside of 127.92 percent. KPTI stock price is now 19.42% away from the 50-day moving average and -9.81% away from the 200-day moving average. The market capitalization of the company currently stands at $430.96M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Among analysts, 4 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $8.89 as their price target over the next twelve months.
With the price target of $8, Piper Sandler recently initiated with Overweight rating for Karyopharm Therapeutics Inc. (NASDAQ: KPTI). On November 04, 2022, RBC Capital Mkts Upgraded its previous ‘Sector Perform’ rating to ‘Outperform’ on the stock increasing its target price from $7 to quote $10, while ‘JP Morgan’ rates the stock as ‘Neutral’.
In other news, Paulson Richard A., President and CEO sold 3,506 shares of the company’s stock on Mar 06. The stock was sold for $11,079 at an average price of $3.16. Upon completion of the transaction, the President and CEO now directly owns 820,116 shares in the company, valued at $3.21 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, President and CEO Paulson Richard A. sold 33,033 shares of the business’s stock. A total of $100,064 was realized by selling the stock at an average price of $3.03. This leaves the insider owning 823,622 shares of the company worth $3.23 million. Insiders disposed of 679,755 shares of company stock worth roughly $2.66 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KPTI stock. A new stake in Karyopharm Therapeutics Inc. shares was purchased by AVIDITY PARTNERS MANAGEMENT LP during the first quarter worth $33,815,000. ARMISTICE CAPITAL, LLC invested $13,526,000 in shares of KPTI during the first quarter. In the first quarter, IRON TRIANGLE PARTNERS LP acquired a new stake in Karyopharm Therapeutics Inc. valued at approximately $6,763,000. CVI HOLDINGS, LLC acquired a new stake in KPTI for approximately $4,396,000. OPALEYE MANAGEMENT INC. purchased a new stake in KPTI valued at around $4,236,000 in the second quarter. In total, there are 219 active investors with 88.20% ownership of the company’s stock.
A candlestick chart of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) showed a price of $3.5400 on Wednesday morning. During the past 12 months, Karyopharm Therapeutics Inc. has had a low of $2.45 and a high of $8.63. The fifty day moving average price for KPTI is $3.2826 and a two-hundred day moving average price translates $4.3464 for the stock.
The latest earnings results from Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.45, beating analysts’ expectations of -$0.57 by 0.12. This compares to $0.52 EPS in the same period last year. The company reported revenue of $33.58 million for the quarter, compared to $126.27 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -73.41 percent. For the current quarter, analysts expect KPTI to generate $35.12M in revenue.
Karyopharm Therapeutics Inc.(KPTI) Company Profile
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
